Revolution Medicines Files 8-K on Financials & Reg FD Disclosure

Ticker: RVMDW · Form: 8-K · Filed: Jan 9, 2024 · CIK: 1628171

Revolution Medicines, Inc. 8-K Filing Summary
FieldDetail
CompanyRevolution Medicines, Inc. (RVMDW)
Form Type8-K
Filed DateJan 9, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: financial-condition, regulation-fd, corporate-disclosure

TL;DR

**RVMD just filed an 8-K, expect financial news or other key disclosures soon!**

AI Summary

Revolution Medicines, Inc. filed an 8-K on January 9, 2024, to disclose information under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). This filing indicates that the company is likely releasing financial updates or other material non-public information, which could impact its stock price (RVMD) on The Nasdaq Stock Market LLC. Investors should pay close attention to the specific details of the financial condition and other disclosures that will be made public, as these could signal future performance or strategic changes.

Why It Matters

This filing signals that Revolution Medicines is about to release important financial or operational news, which could directly influence its stock price and investor sentiment. Understanding the details of this disclosure is crucial for assessing the company's current health and future prospects.

Risk Assessment

Risk Level: medium — The risk is medium because while the filing itself is procedural, the content it refers to (financial condition and Regulation FD disclosure) could contain highly impactful news, positive or negative.

Analyst Insight

A smart investor would await the specific details of the financial condition and Regulation FD disclosures that this 8-K foreshadows. They should then analyze these details to understand the company's current performance and any forward-looking statements before making investment decisions.

Key Players & Entities

  • Revolution Medicines, Inc. (company) — the registrant filing the 8-K
  • RVMD (company) — trading symbol for Revolution Medicines, Inc.
  • The Nasdaq Stock Market LLC (company) — exchange where RVMD common stock is registered
  • January 9, 2024 (date) — date of earliest event reported and filing date

FAQ

What specific items did Revolution Medicines, Inc. report on in this 8-K filing?

Revolution Medicines, Inc. reported on Item 2.02, 'Results of Operations and Financial Condition,' and Item 7.01, 'Regulation FD Disclosure,' as indicated in the 'ITEM INFORMATION' section of the filing.

What is the trading symbol and the exchange where Revolution Medicines, Inc.'s common stock is registered?

The trading symbol for Revolution Medicines, Inc. is RVMD, and its common stock is registered on The Nasdaq Stock Market LLC (Nasdaq Global Select Market), as stated under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 9, 2024, as specified under 'Date of Report (Date of earliest event reported): January 9, 2024'.

What is the business address and phone number of Revolution Medicines, Inc.?

Revolution Medicines, Inc.'s business address is 700 Saginaw Drive, Redwood City, California 94063, and its telephone number is (650) 481-6801, according to the filing.

Is Revolution Medicines, Inc. considered an emerging growth company based on this filing?

The filing indicates that Revolution Medicines, Inc. is NOT checking the box for 'emerging growth company,' suggesting it does not meet that definition as per Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Filing Stats: 833 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-01-09 14:15:37

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share RVMD The Nasdaq

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 9, 2024, Revolution Medicines, Inc. (the "Company") posted a corporate presentation to the investor section of the Company's website at: ir.revmed.com/events-and-presentations. The Company's corporate presentation is attached hereto as Exhibit 99.1. The information furnished under this Item 2.02 and in the presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section or Sections 11 or 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 2.02 and in the presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities and Exchange Commission (the "SEC") made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 9, 2024, the Company posted a corporate presentation to the investor section of the Company's website at: ir.revmed.com/events-and-presentations. The Company's corporate presentation is attached hereto as Exhibit 99.1. The furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the slides is summary information that is intended to be considered in the context of more complete information included in the Company's filings with the SEC and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the slide titled "Legal Disclaimer" in Exhibit 99.1 attached hereto. The information furnished under this Item 7.01 and in the presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section or Sections 11 or 12(a)(2) of the Securities Act. The information contained in this Item 7.01 and in the presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Company presentation dated January 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVOLUTION MEDICINES, INC. Date: January 9, 2024 By: /s/ Jack Anders Jack Anders Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.